4 Midcap High ROE and Fast Revenue Growth Stocks to Watch for Future Multibagger Potential: Ashok Leyland, Dixon, Kalyan Jewellers and Ajanta Pharma

High ROE and fast revenue growth stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Ashok Leyland, Dixon, Kalyan Jewellers and Ajanta Pharma meet that test, with market caps from Rs 43,549 crore to Rs 86,320 crore and Ashok Leyland offering the lowest PE of the group at 23.15. Each of these companies has a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and a return on equity of at least 20 per cent and FY26 revenue growth of at least 15 per cent and profit growth in FY26 and in the latest quarter, and net profit rose in FY26 and in the latest quarter.

This list covers companies with a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and a return on equity of at least 20 per cent and FY26 revenue growth of at least 15 per cent and profit growth in FY26 and in the latest quarter, rising profit in FY26 and the latest quarter, and complete, verifiable financials, ranked by market capitalisation. Each company has a market cap between Rs 30,000 crore and Rs 1 lakh crore. Investors screening high ROE and fast revenue growth stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 29 October 2026 and are drawn from NSE and BSE data and company filings.

Click Here – Get Free Investment Predictions

What Are High ROE and Fast Revenue Growth Stocks and Why Do They Attract Multibagger Interest?

High ROE and fast revenue growth stocks are shares of mid sized companies that earn twenty per cent or more on shareholder money and also grew sales by fifteen per cent or more in FY26, a mix of quality and speed. The four here cover commercial vehicles, electronics manufacturing, jewellery retail and pharmaceuticals.

A high return on equity shows that the company uses shareholder money well, and fast revenue growth shows that demand is rising, so the two together point to a strong compounding business. Within high ROE and fast revenue growth stocks, the four companies show rising profit. For high ROE and fast revenue growth stocks, both FY26 and the latest quarter showed growth. Whichever way you read high ROE and fast revenue growth stocks, the common thread is rising profit backed by complete financial data. With high ROE and fast revenue growth stocks, comparing valuation, growth and balance sheet strength together works better than relying on one number. Every company in the table below passed a rising-profit check, and the figures for high ROE and fast revenue growth stocks are complete. Read each company's latest results and exchange filings before acting on high ROE and fast revenue growth stocks.

High ROE and Fast Revenue Growth Stocks at a Glance: Price, Market Cap, PE, ROE and Price to Book

Prices are closing prices as of 29 October 2026. Ashok Leyland has the lowest PE of the group at 23.15, while Dixon posts the highest return on equity at 30.76%.

Stock	CMP (Rs)	Market Cap (Rs Cr)	PE	Industry PE	ROE	Price to Book	52-Week Range (Rs)
Ashok Leyland	145	86,320	23.15	23.62	24.37%	6.06	134.21 to 215.42
Dixon Technologies	11,488	77,644	37.30	45.19	30.76%	16.61	9,600.00 to 17,299.00
Kalyan Jewellers India	515	53,822	37.52	46.75	21.41%	8.53	327.05 to 648.95
Ajanta Pharma	3,459.70	43,549	38.37	36.35	23.33%	9.62	2,380.20 to 3,796.00

Ashok Leyland: Return on Equity of 24.37%

Ashok Leyland makes trucks, buses and defence vehicles and is among the largest commercial vehicle makers in India. It reported FY26 revenue of Rs 56,946.90 crore, up 16.47% year on year, and net profit of Rs 3,720.98 crore, up 10.00%. Revenue has compounded at 21.28% a year since FY22. Operating margin was 19.17% in FY26.

In the June 2026 quarter, revenue rose 12.29% to Rs 13,258.24 crore and net profit grew 1.53% to Rs 667.77 crore. The share price has gained 106.37% over five years. Domestic institutions raised their holding from 13.61% in July 2025 to 15.76% in June 2026. The stock trades at a PE of 23.15 against an industry PE of 23.62, below the sector average, with a return on equity of 24.37%. The dividend yield is 2.38%.

Dixon: 71.44% Profit CAGR Since FY22

Dixon Technologies is an electronics manufacturing services company that makes televisions, phones, appliances and lighting for brands. It reported FY26 revenue of Rs 49,585.84 crore, up 27.53% year on year, and net profit of Rs 1,644.25 crore, up 33.40%. Net profit has compounded at 71.44% a year since FY22, while revenue has grown 46.72% a year. Operating margin was 3.95% in FY26. The debt-to-equity ratio is 0.21.

The stock trades at a PE of 37.30 against an industry PE of 45.19, below the sector average, with a return on equity of 30.76%. In the June 2026 quarter, revenue rose 25.23% to Rs 16,075.95 crore and net profit grew 156.35% to Rs 717.83 crore. The share price has gained 114.81% over five years.

Kalyan Jewellers: 56.69% Profit CAGR Since FY22

Kalyan Jewellers is one of the largest jewellery retailers in India, with showrooms across India and the Middle East. It reported FY26 revenue of Rs 35,950.88 crore, up 42.72% year on year, and net profit of Rs 1,350.39 crore, up 89.09%. Net profit has compounded at 56.69% a year since FY22, while revenue has grown 34.90% a year. Operating margin was 7.62% in FY26.

In the June 2026 quarter, revenue rose 45.52% to Rs 10,644.67 crore and net profit grew 32.03% to Rs 348.67 crore. The share price has gained 618.28% over five years and 14.90% over the past year. Promoters hold 62.85%, which keeps ownership stable. The stock trades at a PE of 37.52 against an industry PE of 46.75, below the sector average, with a return on equity of 21.41%.

Ajanta Pharma: Return on Equity of 23.33%

Ajanta Pharma sells branded generics in ophthalmology, dermatology, cardiology and pain management in India, Africa and Asia. It reported FY26 revenue of Rs 5,624.93 crore, up 18.60% year on year, and net profit of Rs 1,056 crore, up 14.73%. Net profit has compounded at 10.33% a year since FY22, while revenue has grown 12.94% a year. Operating margin was 28.74% in FY26. The debt-to-equity ratio is 0.06, which keeps interest costs low.

The stock trades at a PE of 38.37 against an industry PE of 36.35, with a return on equity of 23.33%. In the June 2026 quarter, revenue rose 27.68% to Rs 1,696.86 crore and net profit grew 30.89% to Rs 334.22 crore. The share price has gained 125.31% over five years and 35.42% over the past year. Domestic institutions raised their holding from 17.90% in September 2025 to 21.94% in September 2026.

High ROE and Fast Revenue Growth Stocks: Financial Comparison on Growth and Margins

The table compares scale and growth across these high ROE and fast revenue growth stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.

Stock	Revenue (Rs Cr)	Net Profit (Rs Cr)	Revenue Growth (YoY)	4-Year Revenue CAGR	Latest Quarter Revenue Growth	Operating Margin (Latest Quarter)
Ashok Leyland	56,946.90	3,720.98	16.47%	21.28%	12.29%	20.01%
Dixon	49,585.84	1,644.25	27.53%	46.72%	25.23%	6.43%
Kalyan Jewellers	35,950.88	1,350.39	42.72%	34.90%	45.52%	6.50%
Ajanta Pharma	5,624.93	1,056	18.60%	12.94%	27.68%	30.41%

Check the Univest Screener for live data on these high ROE and fast revenue growth stocks

Institutional Holding in Ashok Leyland, Dixon, Kalyan Jewellers and Ajanta Pharma

Institutional holding shows who is backing these high ROE and fast revenue growth stocks alongside the promoter. The table uses the latest reported quarter for each. Dixon has the deepest institutional backing, with FII and DII together holding 47.67% as of September 2026. Domestic institutions increased their holding over the past year in Ashok Leyland (from 13.61% to 15.76%) and Ajanta Pharma (from 17.90% to 21.94%).

Stock	Promoter	FII	DII	Public	Quarter
Ashok Leyland	51.51%	20.68%	15.76%	12.05%	June 2026
Dixon	28.50%	18.96%	28.71%	23.83%	September 2026
Kalyan Jewellers	62.85%	13.83%	14.41%	8.91%	September 2026
Ajanta Pharma	63.47%	7.63%	21.94%	6.96%	September 2026

Risks to Weigh in High ROE and Fast Revenue Growth Stocks

Being careful with high ROE and fast revenue growth stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:

• Past growth may not repeat.
• Share prices can move sharply in either direction.
• Valuation: Ajanta Pharma trades at a PE of 38.37 against an industry PE of 36.35, so earnings need to keep growing to support the price.
• Concentration: Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.

How to Choose Between High ROE and Fast Revenue Growth Stocks

Picking from high ROE and fast revenue growth stocks comes down to four checks, applied in order.

1. Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
2. Compare each PE with the industry PE (23.62 to 46.75) and ask whether the growth rate justifies any gap.
3. Track net profit growth, the operating margin and the return on equity in every quarterly result.
4. Stagger entries across quarters and review institutional holding every reporting season.

Download the Univest iOS App or Univest Android App to track Ashok Leyland, Dixon, Kalyan Jewellers and Ajanta Pharma live prices.

Conclusion

Among high ROE and fast revenue growth stocks, Ashok Leyland stands out for the lowest PE of the group at 23.15, Dixon for the highest return on equity at 30.76%, Kalyan Jewellers for the biggest five-year price gain at 618.28% and Ajanta Pharma for a nearly debt-free balance sheet, with a debt-to-equity ratio of 0.06. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing high ROE and fast revenue growth stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.

Frequently Asked Questions on High ROE and Fast Revenue Growth Stocks to Watch

Which are the best high ROE and fast revenue growth stocks to watch for multibagger potential?

Ans. Ashok Leyland, Dixon, Kalyan Jewellers and Ajanta Pharma are the 4 names this list highlights, with market caps of Rs 86,320 crore, Rs 77,644 crore, Rs 53,822 crore and Rs 43,549 crore respectively. Ashok Leyland is notable for the lowest PE of the group at 23.15. Dixon stands out for the highest return on equity at 30.76%. Kalyan Jewellers offers the biggest five-year price gain at 618.28%. Ajanta Pharma brings a nearly debt-free balance sheet, with a debt-to-equity ratio of 0.06. These are watchlist names for high ROE and fast revenue growth stocks, not recommendations, so match each one to your own risk profile and time horizon.

Is Dixon a good stock for long-term investors?

Ans. Dixon has a return on equity of 30.76%, a PE of 37.30 against an industry PE of 45.19 and a market cap of Rs 77,644 crore. Net profit has compounded at 71.44% a year since FY22, and FY26 revenue rose 27.53% while June 2026 quarter net profit grew 156.35%. Long-term returns in high ROE and fast revenue growth stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.

Can Kalyan Jewellers become a multibagger from here?

Ans. Kalyan Jewellers has already gained 618.28% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in high ROE and fast revenue growth stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 56.69% a year since FY22, and FY26 revenue rose 42.72%. At a PE of 37.52 against an industry PE of 46.75, valuation should be checked against that growth before investing.

What is the market cap of Ashok Leyland, Dixon, Kalyan Jewellers and Ajanta Pharma?

Ans. As of 29 October 2026, Ashok Leyland has a market cap of Rs 86,320 crore, Dixon has a market cap of Rs 77,644 crore, Kalyan Jewellers has a market cap of Rs 53,822 crore and Ajanta Pharma has a market cap of Rs 43,549 crore. All of them qualify as midcaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on high ROE and fast revenue growth stocks.

What are the risks of investing in high ROE and fast revenue growth stocks?

Ans. The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Ajanta Pharma trades at a PE of 38.37 against an industry PE of 36.35, so earnings growth needs to hold up.

Is Ashok Leyland trading below its industry PE?

Ans. Ashok Leyland trades at a PE of 23.15 against an industry PE of 23.62. A lower PE means investors pay less for each rupee of earnings, but it should be read with growth (FY26 revenue rose 16.47% and June 2026 quarter net profit grew 1.53%) and balance sheet strength before drawing a conclusion.

How much do institutions hold in Ashok Leyland, Dixon, Kalyan Jewellers and Ajanta Pharma?

Ans. As of the latest reported quarter, FII and DII together hold 36.44% of Ashok Leyland (20.68% and 15.76%), 47.67% of Dixon (18.96% and 28.71%), 28.24% of Kalyan Jewellers (13.83% and 14.41%) and 29.57% of Ajanta Pharma (7.63% and 21.94%). Rising institutional holding is a useful signal in high ROE and fast revenue growth stocks, though it should be read with earnings trends rather than on its own.